Skip to main content
SpringerLink
Log in

Methodological arguments for the necessity of randomized trials in high-dose chemotherapy for breast cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

In the past ten years high-dose chemotherapy with autologous haematopoetic stem-cell support (HD-CT) has increasingly been used for breast cancer. But the vast majority of trials are small phase I/II studies showing until now not enough evidence that HD-CT is superior to conventional-dose chemotherapy (CD-CT). In contrast to this, the public perception of this treatment is different. Patients as well as physicians often uncritically believe in reports contrasting the positive results obtained in case series treated by HD-CT with those of historical control groups. This leads to the problem that many patients and also clinicians are not willing to participate in randomized trials on this topic.

A critical assessment of current knowledge on the effectiveness of HD-CT in breast cancer is given. The problems related to the use of historical controls, in general, and especially in the setting of HD-CT are demonstrated. Using data of patients treated with CD-CT within trials of the German Breast Cancer Study Group (GBSG) it will be shown that results similarly favorable to those reported from patients treated with a high-dose regimen may be produced using quite simple selection mechanisms.

Comparisons of patients treated with HD-CT with historical control groups of patients treated with CD-CT may be misleading. A valid treatment comparison is only possible by means of large randomized trials. Clinicians should participate in the ongoing trials and enter all eligible patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Smith GA, Henderson IC: High-dose chemotherapy (HDC) with autologous bone marrow transplantation (AMBT) for the treatment of breast cancer: The jury is still out. In: DeVita VT, Hellman S, Rosenberg SA (eds) Important Advances in Oncology. Philadelphia, Lippincott, 1995, pp 201–214

  2. Zujewski J, Nelson A, Abrams J: Much ado about not ::: enough data: high-dose chemotherapy with autologous stem cell rescue for breast cancer. J Natl Cancer Inst 90: 200–209, 1998

    Google Scholar 

  3. Matthews J: NCI Survey explores the M.D.'s perspective on ABMT trials (News). J Natl Cancer Inst 87: 1510–1511, 1995

    Google Scholar 

  4. Gradishar WJ, Tallman MS, Abrams JS: High-dose chemotherapy for breast cancer. Ann Int Med 125: 599–604, 1996

    Google Scholar 

  5. Smigel K:Women flock to ABMT for breast cancer without final proof (News). J Natl Cancer Inst 87: 952–955, 1995

    Google Scholar 

  6. Schmoor C, Schumacher M: High-dose chemotherapy as adjuvant treatment for breast cancer – some statistical arguments. Onkologie 19: 78–80, 1996

    Google Scholar 

  7. Schumacher M, Bastert G, Bojar H, Hübner K, Olschewski M, Sauerbrei W, Schmoor, C, Beyerle C, Neumann RLA, Rauschecker HF, for the German Breast Cancer Study Group (GBSG): Randomized 22 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. J Clin Oncol 12: 2086–2093, 1994

    Google Scholar 

  8. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 13: 2483–2489, 1995

    Google Scholar 

  9. Kennedy MJ: High-dose chemotherapy of breast cancer: Is the question answered? (Editorial). J Clin Oncol 13: 2477–2479, 1995

    Google Scholar 

  10. Recht A: High-dose chemotherapy for metastatic breast cancer. J Clin Oncol 14: 684–685 (letter), 1996

    Google Scholar 

  11. Cohen MH: Dose-intensive metastatic breast cancer chemotherapy. J Clin Oncol 14: 685–686 (letter), 1996

    Google Scholar 

  12. Subar M: Risk stratification for high-dose chemotherapy in metastatic breast cancer. J Clin Oncol 14: 686–687 (letter), 1996

    Google Scholar 

  13. Spiridonidis CH, Laufman LR, Rhodes V, Jones J: Highdose chemotherapy for metastatic breast cancer. J Clin Oncol 14: 686 (letter), 1996

    Google Scholar 

  14. Peters WP, Jones RB, Vredenburgh J, Shpall EJ, Hussein A, Elkordy M, Rubing P, Ross M, Berry D: A large prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicinbased induction therapy (AFM). Proc Am Soc Clin Oncol 15: 121 (abstr), 1996

    Google Scholar 

  15. Antman KH, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK, Freytes CO, Gale RP, Hillner BE, Holland HK, Kennedy MJ, Klein JP, Lazarus HM, McCarthy PL Jr, Saez R, Spitzer G, Stadtmauer EA, Williams SF, Wolff S, Sabocinski KA, Armitage JO, Horowitz MM: High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 15: 1870–1879, 1997

    Google Scholar 

  16. Peters WP, Ross M, Vredenburgh JJ, Meidenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC Jr, Jones R, Shpall E, Wu K, Rosner G, Gilbert C, Mathias B, Coniglio D, Petros W, Henderson IC, Norton L, Weiss RB, Budman D, Hurd D: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11: 1132–1143, 1993

    Google Scholar 

  17. Peters WP, Dansey R, Klein J, Berry D: High-dose chemotherapy for high-risk primary breast cancer. In: Salmon SE (ed) Adjuvant Therapy of Cancer VIII. Philadelphia, Lippincott, 1997, pp 117–122

  18. Zander A, Krüger W, Zeller W, Jonat W, Hossfeld D: Hochdosischemotherapie und autologe Blutstammzelltransplantation (APBSCT) beim Mammakarzinom. Intensivmedizin im Dialog-Sonderheft Onkologie 17: 1–4, 1994

    Google Scholar 

  19. Kanz L, Brugger W: Hochdosischemotherapie beim Mammakarzinom. Onkologie 1: 229–232, 1995

    Google Scholar 

  20. Hurd DD, Peters WP, for the Cancer and Leukemia Group B: Randomized, comparative study of high-dose (with autologous bone marrow support) versus low-dose cyclophosphamide, cisplatin and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable stage II or III breast cancer involving 10 or more axillary lymph nodes (CALGB 38 C Schmoor and M Schumacher Protocol 9082). J Natl Cancer Inst Monographs 19: 41–44, 1995

    Google Scholar 

  21. Peters WP: High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer: Yes. In: DeVita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology, Philadelphia, Lippincott, 1995, pp 215–230

  22. Byar DP, Simon RM, Friedewald WT, Schlesselman JJ, DeMets DL, Ellenberg JH, Gail M, Ware JH: Randomized clinical trials: perspectives on some recent ideas. N Engl J Med 295: 74–80, 1976

    Google Scholar 

  23. Pocock SJ: Clinical Trials. New York, Wiley, 1983.

    Google Scholar 

  24. Green SB, Byar DP: Using observational data from registries to compare treatments: the fallacy of omnimetrics. Stat Med 3: 361–370, 1984

    Google Scholar 

  25. Crump M, Goss PE, Prince M, Girourard C: Outcome of extensive evaluation before adjuvant therapy inwomen with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol 14: 66–69, 1996

    Google Scholar 

  26. Rahman ZU, Frye DK, Buzdar AU, Hortobagyi G: A retrospective analysis to evaluate the impact of selection process for high-dose chemotherapy on the outcome of patients with metastatic breast cancer. Proc Am Soc Clin Oncol 14: 94 (abstr), 1995

  27. Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE, Hortobagyi GN: Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standarddose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 15: 3171–3177, 1997

    Google Scholar 

  28. Garcia-Carbonero R, Hidalgo M, Paz-Ares L, et al.: Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. J Clin Oncol 15: 3178–3184, 1997

    Google Scholar 

  29. Schmoor C, Olschewski M, Schmacher M: Randomized and non-randomized patients in clinical trials: Experiences with comprehensive cohort studies. Stat Med 15: 263–271, 1996

    Google Scholar 

  30. Bloom HJS, Richardson WW: Histological tumor grading and prognosis in breast cancer. Br J Cancer 11: 339–377, 1957

    Google Scholar 

  31. McCarthy M: Unproven breast-cancer therapy widely used in USA. Lancet 347: 1617, 1996

    Google Scholar 

  32. de Vries EGE, ten Vergert EM, Mastenbroek CG, Dalesio O, Rodenhuis S: Breast cancer studies in the Netherlands (letter). Lancet 348: 407–408, 1996

    Google Scholar 

  33. Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Koning CCE, Peterse JL, Borger JH, Nooijen WJ, Bakx R, Dalesio O, Rutgers E: Randomized trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 352: 515–521, 1998

    Google Scholar 

  34. Hortobagyi GN, Buzdar AU, Champlin R, Gajewski J, Holmes FA, Booser D, Valero V, Theriault RL: Lack of efficacy of adjuvant high-dose (HD) tandem combination chemotherapy (CT) for high-risk primary breast cancer (HRPBC): a randomized trial. Proc Am Soc Clin Oncol 17: (abstr 417), 1998

Download references

Author information

Authors and Affiliations

  1. Institute of Medical Biometry and Medical Informatics, University of Freiburg, Germany

    Claudia Schmoor & Martin Schumacher

Authors
  1. Claudia Schmoor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Schumacher
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmoor, C., Schumacher, M. Methodological arguments for the necessity of randomized trials in high-dose chemotherapy for breast cancer. Breast Cancer Res Treat 54, 31–38 (1999). https://doi.org/10.1023/A:1006111821492

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006111821492

Search

Navigation